Roberto Calle, MD, FACE, FACP is Co-Chair of the Metabolic Diseases Steering Committee for the FNIH Biomarkers Consortium and Executive Director in Clinical Research with the Cardiovascular and Metabolic Diseases Research Unit at Pfizer Biomedical Institute in Cambridge, MA.
The Foundation for the National Institutes of Health procures funding and manages alliances with public and private institutions in support of the mission of the National Institutes of Health (NIH). The FNIH was established by Congress as a not-for-profit 501(c)(3) charitable organization to facilitate groundbreaking research at the NIH and worldwide. As an independent organization, it raises private funds and creates public private partnerships to support the mission of the NIH—making important discoveries that improve health and save lives. The Biomarkers Consortium is one of the FNIH’s preeminent research partnerships, and its mission is to develop and support research aimed at ultimately qualifying promising biomarkers for use in drug development, diagnosing disease, predicting therapeutic response or improving clinical practice. This is accomplished by creating partnerships that combine the forces of the public and private sectors. All its projects sit in the pre-competitive space, with results made public for the purpose of advancing the Consortium’s goals.
Dr. Calle joined the Biomarkers Consortium’s Metabolic Disorders Steering Committee as Pfizer’s representative in 2009 and has been the Committee’s Co-Chair, representing industry, since 2013. The Metabolic Disorders Steering Committee currently sponsors multiple biomarker initiatives in the areas of diabetes, osteoporosis, cardiovascular disease and sarcopenia.
Dr. Calle obtained a Bachelor of Science in Biology and a Doctor of Medicine degree from the University of Puerto Rico. He completed specialty training in Internal Medicine at the University of Michigan Medical School and sub-specialty training in Endocrinology and Metabolism at Yale University School of Medicine. After 12 years in academia as faculty at Yale and later at the Medical College of Georgia, he joined Pfizer, Inc. to focus on clinical research and translational medicine in metabolic diseases. Dr. Calle has been involved in drug development spanning phase 1, 2 and 3; including work in the areas of type 2 diabetes, diabetic complications, dyslipidemia, obesity and NASH. He is currently the sponsor for the FNIH NASH Biomarkers Initiative.